check_circleStudy Completed
Hirsutism, Dermatitis, Seborrheic Alopecia, Severe Acne, Seborrhea
Bayer Identifier:
17194
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study on the Prescribing Indications for combinations of cyproterone acetate and ethinylestradiol in 5 European Countries
Trial purpose
This study is designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers. The primary objective of the study is to characterize the prescribing behaviors for Cyproterone Acetate combined with Ethinyl Estradiol in 5 European countries (Austria, Czech Republic, France, the Netherlands, and Spain), including:
•prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol
•use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the updated label
•concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined hormonal contraceptives
•second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the indication acne
•prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol
•use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the updated label
•concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined hormonal contraceptives
•second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the indication acne
Key Participants Requirements
Sex
FemaleAge
NaN - N/ATrial summary
Enrollment Goal
1408Trial Dates
March 2015 - May 2016Phase
N/ACould I Receive a placebo
NoProducts
Diane 35 (EE/CPA, BAY86-5264)Accepts Healthy Volunteer
NoPrimary Outcome
- Drug utilization pattern of CPA/EEdate_rangeTime Frame:within 6 monthsenhanced_encryptionNoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A